Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes

Scandinavian Journal of Immunology

Volumn 43, Issue 4, 1996, Pages 449-455

  Yacyshyn, B R ^a   Bowen Yacyshyn, M B ^a   Pilarski, L M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLYCOPROTEIN P; RAPAMYCIN;

ADULT; ARTICLE; B LYMPHOCYTE; CELL LINE; DRUG TRANSPORT; HUMAN; HUMAN CELL; IMMUNOMODULATION; MULTIDRUG RESISTANCE; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029867449     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1996.d01-52.x     Document Type: Article

References (60)

1. Gros P, Shustik C. Multidrug resistance. A novel class of membrane-associated transport proteins is identified. In: Bell JC, Sonenberg N, eds. Miniseries in Molecular Biology. Cancer Invest 1991;9:563-9.
2. Gill DR, Hyde SC, Higgins CF, Valverde MA, Mintenig GM, Sepulveda FV. Separation of drug transport and chloride channel functions of the human multidrug resistance P-glycoprotein. Cell 1992;71:23-32.
3. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993;62:385-427.
4. Doige CA, Ames GF. ATP-dependent transport systems in bacteria and humans: Relevance to cystic fibrosis and multidrug resistance. Ann Rev Microbiol 1993;47:291-319.
5. Higgins CF. The mullidrug resistance P-glycoprotein. Current Opin Cell Biol 1993;5:684-7.
6. Endicolt JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Ann Rev Biochem 1989;58:137-71.
7. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
8. Ichikawa-Haraguchi M, Sumizawa T, Yoshimura A. Progesterone and its metabolites: the potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland. Biochim Biophys Acta 1993;1158:201-8.
9. Arceci RJ, Croop JM, Horwitz SB, Housman D. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988;85:4350-4.
10. Ueda K, Okamura N, Hirai M et al. Human P-glycoprotein transports cortisol, aldosterone and dexamethasone but not progesterone. J Biol Chem 1992;267:24248-52.
11. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human haematopoietic stem cells. Cell 1991;66:85-94.
12. Gupta S, Kim CH, Tsuruo T, Gollapudi S. Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8+ T cells: a role in cytotoxic effector function. J Clin Immunol 1992; 12:451-8.
13. Gupta S, Gollapudi S. P-glycoprotein (MDRl gene product) in cells of the immune system: Its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol 1993;13:289-301.
14. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992;80:2735-9.
15. Pilarski LM, Cass CE, Tsuro T, Belch AR. Multidrug resistance of a continuously differentiating monoclonal B lineage in the blood and bone marrow of patients with multiple myeloma. Curr Top Microbiol Immunol 1992;182:177-85.
16. Pilarski LM, Belch AJ. Circulating monoclonal B cells expressing P-glycoprotein may be a reservoir of mullidrug resistant disease in multiple myeloma. Blood 1994;83:724-36.
17. Pilarski LM, Paine D, McElhaney JE, Cass CE, Belch AR. Multidrug transporter P-glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: modulation with differentiation stage and during aging. Am J Hematol 1995;49:323-35.
18. Cordon-Cardo C, O'Brien JP, Casals D et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8.
19. Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 1992;267:20383-91.
20. Ito S, Woodland C, Harper PA, Koren G. P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. Life Sci 1993;53:25-31.
21. Higgins CF. ABC transporters: from microorganisms to man. Ann Rev Cell Biol 1992;8:67-113.
22. Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chlorine channels associated with the human multidrug-resistance P-glycoprotein. Nature 1992;355:830-3.
23. Abraham EH, Prat AG, Gerweck L et al. The multidrug resistance (MDR1) gene product functions as an ATP channel. Proc Natl Acad Sci USA 1993;90:312-16.
24. Spies T, Bresnahan M, Bahram S et al. A gene in the human major histocompatibility complex class Il region controlling the class I antigen presentation pathway. Nature 1990;348:744-7.
25. Monaco JJ, Cho S, Attaya M, Transport protein genes in the murine MHC: possible implications for antigen processing. Science 1990;250:1723-6.
26. Kelly A, Powis SH, Kerr L et al. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature 1992;355:641-4.
27. Deverson EV, Gow IR, Coadwell WJ, Monaco JJ, Butcher GW, Howard JC. MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters. Nature 1990;348:738-41.
28. Sharma RC, Inoue S, Roitelman J, Schimke RT, Simoni RD. Peptide transport by the multidrug resistance pump. J Biol Chem 1992;267:5731-4.
29. Raymond M, Gros P, Whiteway M, Thomas DY. Functional complementation of yeast STE6 by a mammalian multidrug resistance MDR gene. Science 1992;256:232-4.
30. Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986;47:371-80.
31. Naito M, Oh-hara T, Yamazaki Y, Danki T, Tsuruo T. Reversal of multidrug resistance by an immunosuppressive agent FK 506. Cancer Chemother Pharmacol 1992;29:195-200.
32. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporine A and FK 506. J Biol Chem 1993;268:6077-80.
33. Arceci RJ, Stieglitz F, Bierer BE. Immunosuppressants FK 506 and Rapamycin function as reversal agents for the multidrug resistance phenotype. Blood 1992;80:1528-36.
34. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. P-glycoprotein-mediated transcellular transport of MDR-reversing agents. FEBS Letts 1993;324:99-102.
35. Lelong IH, Guzikowski AP, Haugland RP, Pastan I, Gottesman MM, Willingham MC. Fluorescent verapamil derivative for monitoring activity of the multidrug transporter. Molec Pharmacol 1991;40:490-4.
36. Goldberg H, Ling V, Wong PY, Skorecki K. Reduced cyclosporine accumulation in multidrug-resistant cells. Biochem Biophys Res Comm 1988;152:552-8.
37. Foxwell BM, Mackie A, Ling V, Ryffel B. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Molec Pharmacol 1989;36:543-6.
38. Rao US, Scarborough GA. Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Molec Pharmacol 1994;45:773-6.
39. Kay JE, Kromwel L, Doe SE, Denyer M. Inhibition of T and B-lymphocyte proliferation by Rapamycin. Immunology 1991;72:544-9.
40. Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, Rapamycin. Transplantation 1991;52:185-91.
41. Hoof T, Demmer A, Hadam MR, Riordan JR, Tummler B. Reversal of multidrug resistance in Chinese hamster ovary cells by the immunosuppressive agent Rapamycin. Eur Pharmacol 1993;246:53-8.
42. Yacyshyn BR, Pilarski LM. Expression of CD45RO on circulating CD19+ B cells in Crohn's disease. Gut 1993;34:1698-704.
43. Yacyshyn BR, Lazarovits A, Tsai V, Matejko K. Crohn's, ulcerative colitis and normal intestinal lymphocytes express integrins in a dissimilar pattern. Gastroenterology 1994;107: 1364-71.
44. Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in Vinca alkaloid resistant human leukemic lymphoblasts. Cancer Res 1979;39:2070-6.
45. Yakimets WJ, Lakey JR, Yatscoff RW et al. Prolongation of canine pancreatic islet allograft survival with combined Rapamycin and cyclosporine therapy at low doses. Rapamycin efficacy is blood level related. Transplantation 1993;56:1293-8.
46. Yatscoff RW, Faraci C, Bolingbroke P. Measurement of rapamycin in whole blood using reverse-phase high-performance liquid chromatography. Therapeutic Drug Monitoring 1992;14:138-41.
47. Schinkel AH, Roelofs MEM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Research 1991;51:2628-35.
48. Nakatsukasa H, Silverman JA, Gant TW, Evarts RP, Thorgeirsson SS. Expression of MDR genes in rat liver during regeneration and after carbon tetrachloride intoxication. Hepatology 1993;18:1202-7.
49. Thorgeirsson SS, Huber BE, Sorrell S, Fojo A, Pastan I, Gottesman MM. Expression of the MDR gene in hepatocarcinogenesis and regenerating rat liver. Science 1987;236:1120-2.
50. Goldman R, Harvey J, Hogg N. VLA-2 is the integrin used as a collagen receptor by leukocytes. Eur J Immunol 1992;22:1109-14.
51. Languino LR, Gehlsen KR, Wayner E, Carter WG, Engvall E, Roushlati E. Endothelial cells use α2β1 integrin as a laminin receptor. J Cell Biol 1989;109:2455-62.
52. Qin Y, Sato TN. Mouse multidrug resistance 1 a/3 gene is the earliest known endothelial cell differentiation marker during blood-brain barrier development. Developmental Dynamics 1995;202:172-80.
53. Kimball PM, Kerman RK, Van Buren B. Cyclosporine and Rapamycin affect protein kinase C induction of the intracellular activation signal; activation of DNA replication. Transplantation 1993;55:1128-32.
54. Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree CR. Rapamycin selectivity inhibits interleukin-2 activation of p70 S6 kinase. Nature 1992;358:70-3.
55. Terada N, Lucas JJ, Szepesi A, Franklin RA, Domenico J, Gelfand EW. Rapamycin blocks cell cycle progression of activated T-cells prior to events characteristic of the middle to late G1 phase of the cycle. J Cell Physiol 1993;154:7-15.
56. Kimball PM, Kerman RH, Kahan BD. Rapamycin and cyclosporine produce synergistic but not identical mechanisms of immunosuppression. Transplant Proc 1991;23:1027-8.
57. Ling V, Kartner N, Sudo T, Siminovitch L, Riordan J. Multidrug resistant phenotype in Chinese hamster ovary cells. Cancer Treat Rep 1983;67:869-74.
58. Schinkel AH, Kemp S, Dolle M, Rudenko G, Wagenaar E. N-Glycosylation and deletion mutants of the human multidrug resistant P-glycoprotein. J Biol Chem 1993;268:7474-81.
59. 2+ -calmodulin. J Biol Chem 1995;270:11040-2.
60. Dias VC, Yatscoff RW. Investigation of rapamycin transport and uptake across absorptive human intestinal cell monolayers. Clin Biochem 1994;27:31-6.